Different low doses of broad‐band UVA in the treatment of morphea and systemic sclerosis

Abstract

After 20 sessions, it appears that lower doses of UVA (5, 10 J/cm(2)) are as beneficial as the relatively higher dose (20 J/cm(2)) in the treatment of M and SS.

Medium-dose is more effective than low-dose ultraviolet A1 phototherapy for localized scleroderma as shown by 20-MHz ultrasound assessment

“…In this respect, the better results obtained with medium-dose UVA1 as detected by ultrasound measurement are of clinical relevance. Similarly, ElMofty et al, 24 comparing 3 doses of broadband UVA (5, 10, and 20 J/cm 2 ), could not find any difference in the clinical response whereas by histopathological examination a more pronounced normalization of the dermal collagen was observed with the two higher UVA doses than with the low dose.…”

Scleroderma: Nomenclature, etiology, pathogenesis, prognosis, and treatments: Facts and controversies

“…[57][58][59][60][61][62][63][64][65][66][67][68][69][70] Deep plaque morphea may require local phototherapy (nb-uvb, UVA, low-and medium-dose UVA1, or psoralen plus UVA [PUVA]) or systemic immunosuppression. 50 If systemic immunosuppression is required, treatment with methotrexate in combination with a prednisone taper is supported by the strongest data.…”

A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma

“…2 Since then, several uncontrolled phototherapeutic trials have been published demonstrating beneficial effects in LS. [3][4][5] In this context, UVA irradiation in the spectrum of 340 to 400 nm, UVA1, has gained special attention and was applied in different dosages. So far, low-dose (LD) and medium-dose (MD) UVA1 seems to be as effective as high-dose UVA1, with a possible better risk/benefit ratio.…”